The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain

Suzanne A.W. Fuqua, D. Craig Allred, Richard M. Elledge, Shelly L. Krieg, Margaret G. Benedix, Zafar Nawaz, Bert W. O'Malley, Geoffrey L. Greene, William L. McGuire

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

We have used in vitro DNA binding assays as a measure of estrogen receptor (ER) function in human breast tumors. We found that the majority of ER+ (25 ER+/progesterone receptor [PgR]+, and 25 ER+/PgR-) tumors we examined were capable of binding consensus estrogen response element (ERE) oligonucleotides in this assay system. We found significant proteolytic activity in many of the tumors such that protease inhibitors were found to be essential during the preparation of tumor extracts. We next applied direct sequence analysis of the ER DNA binding domain of several of these tumors, and determined that the ER+/PgR- breast tumors did not contain mutations within the DNA binding domain which might explain their apparent discordant receptor phenotype. We did identify an alternatively spliced ER variant missing exon 3 of the DNA binding domain. This variant was unable to function as a transcriptional inducer of an estrogen-responsive reporter in a yeast assay system. Furthermore, the exon 3 ER deletion variant was expressed at equivalent levels in all of the ER+ breast tumors, so that it does not appear to be involved in the evolution of the ER+/PgR- breast cancer phenotype.

Original languageEnglish (US)
Pages (from-to)191-202
Number of pages12
JournalBreast cancer research and treatment
Volume26
Issue number2
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Keywords

  • breast cancer
  • DNA binding domain
  • estrogen receptor
  • gel-retardation analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain'. Together they form a unique fingerprint.

  • Cite this

    Fuqua, S. A. W., Allred, D. C., Elledge, R. M., Krieg, S. L., Benedix, M. G., Nawaz, Z., O'Malley, B. W., Greene, G. L., & McGuire, W. L. (1993). The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast cancer research and treatment, 26(2), 191-202. https://doi.org/10.1007/BF00689692